Australia · Delayed Price · Currency is AUD Regis Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
H1 FY2026 saw 18% revenue growth and 4% higher underlying EBITDA, driven by acquisitions and room price increases. Strong cash flow and RAD inflows support ongoing expansion, with margin pressure from funding changes expected to ease as reforms and operational efficiencies take effect.
Fiscal Year 2025
-
Strong FY 2025 financial results and increased dividends were reported, with a clear growth strategy targeting 10,000 beds by FY 2028 through acquisitions and developments. Key governance, funding, and sector challenges were discussed, and all resolutions were put to poll.
-
Strong financial performance with revenue up 15%, EBITDA up 17%, and NPAT up 37% year-over-year, driven by high occupancy, acquisitions, and government funding. Strategic growth continues via acquisitions and greenfield developments, with a focus on operational excellence and meeting new regulatory standards.
-
Strong half-year results with 18% revenue growth, 31% higher EBITDA, and 301% net profit increase, driven by higher occupancy, government funding, and acquisitions. Strategic investments in workforce, technology, and development support continued growth and high occupancy expectations.
Fiscal Year 2024
-
The meeting highlighted strong FY2024 financial results, robust occupancy, and a 96% share price increase. Strategic growth through acquisitions and new developments was emphasized, alongside sector reforms and workforce challenges. All resolutions passed with strong shareholder support.
-
Record revenue and EBITDA growth driven by higher occupancy, government funding, and the CPSM acquisition. Strong cash flow and a robust balance sheet support ongoing expansion, with tight supply-demand dynamics expected to persist and further CapEx planned for FY 2025.